Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 jun 2008 - 08:44
Statutaire naam
Crucell N.V.
Titel
DSM and Crucell Announce Record Achievement in PER.C6® Technology
Bericht
Heerlen/Leiden, The Netherlands, 16 June 2008 - DSM Biologics and
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announce another breakthrough in the production of IgG antibodies using PER.C6® technology. By employing the PER.C6® human cell line and proprietary XD™ technology, a record yield of over 27 grams per liter has been achieved. In March 2008 a yield of 15 grams per liter was reported.
Datum laatste update: 27 juli 2024